抑制剂-话题@MedSci - 梅斯（MedSci）

#抑制剂#

1990篇内容 | 3122人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1853004, encodeId=c1dd185300482, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAMA：消化疾病周（DDW）的亮点——大流行相关的结直肠癌筛查下降、质子泵抑制剂与痴呆症之间缺乏关联等, objectType=article, longId=730634, objectId=be25e3063466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be25e3063466, replyNumber=0, likeNumber=80, createdTime=2023-01-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be25e3063466, moduleTitle=JAMA：消化疾病周（DDW）的亮点——大流行相关的结直肠癌筛查下降、质子泵抑制剂与痴呆症之间缺乏关联等, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=be25e3063466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852957, encodeId=f0f0185295e20, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批, objectType=article, longId=725721, objectId=8aebe257213e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8aebe257213e, replyNumber=0, likeNumber=79, createdTime=2022-11-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8aebe257213e, moduleTitle=重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8aebe257213e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852986, encodeId=c9b5185298648, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效, objectType=article, longId=728252, objectId=27bce282523d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27bce282523d, replyNumber=0, likeNumber=112, createdTime=2023-05-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27bce282523d, moduleTitle=2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=27bce282523d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852939, encodeId=12801852939e5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, objectType=article, longId=724027, objectId=af24e240278a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af24e240278a, replyNumber=0, likeNumber=74, createdTime=2022-12-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af24e240278a, moduleTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=af24e240278a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852972, encodeId=060a18529e2ab, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=黄金靶点NTRK第二代抑制剂VC004初步疗效喜人，国内多家有类似管线, objectType=article, longId=727460, objectId=73cfe2746086, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73cfe2746086, replyNumber=0, likeNumber=72, createdTime=2023-01-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73cfe2746086, moduleTitle=黄金靶点NTRK第二代抑制剂VC004初步疗效喜人，国内多家有类似管线, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=73cfe2746086)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853005, encodeId=3e511853005f1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=这6类人群，该如何使用质子泵抑制剂？, objectType=article, longId=730601, objectId=c9b3e30601ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9b3e30601ae, replyNumber=0, likeNumber=78, createdTime=2022-09-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9b3e30601ae, moduleTitle=这6类人群，该如何使用质子泵抑制剂？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c9b3e30601ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853003, encodeId=348b1853003cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Gastroenterology：接受腹部手术的炎症性肠病患者术前肿瘤坏死因子抑制剂的治疗的安全性分析, objectType=article, longId=730498, objectId=0be2e30498a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be2e30498a9, replyNumber=0, likeNumber=95, createdTime=2022-10-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be2e30498a9, moduleTitle=Gastroenterology：接受腹部手术的炎症性肠病患者术前肿瘤坏死因子抑制剂的治疗的安全性分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0be2e30498a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853025, encodeId=9515185302521, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=梦想照进现实！二代NTRK抑制剂获FDA孤儿药称号, objectType=article, longId=731988, objectId=774ce3198835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=774ce3198835, replyNumber=0, likeNumber=0, createdTime=2022-09-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=774ce3198835, moduleTitle=梦想照进现实！二代NTRK抑制剂获FDA孤儿药称号, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=774ce3198835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852999, encodeId=ffa318529994e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=DOM:IL-8受体CXCR1和CXCR2的抑制剂拉达立辛治疗1型糖尿病, objectType=article, longId=729484, objectId=f922e2948434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f922e2948434, replyNumber=0, likeNumber=67, createdTime=2022-07-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f922e2948434, moduleTitle=DOM:IL-8受体CXCR1和CXCR2的抑制剂拉达立辛治疗1型糖尿病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f922e2948434)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852945, encodeId=a07d185294596, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=109, createdTime=2022-12-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852964, encodeId=ff4718529646d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？, objectType=article, longId=726544, objectId=1e53e265444e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e53e265444e, replyNumber=0, likeNumber=106, createdTime=2022-12-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e53e265444e, moduleTitle=Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1e53e265444e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852993, encodeId=caab1852993b4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！, objectType=article, longId=729099, objectId=c01ae29099c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c01ae29099c1, replyNumber=0, likeNumber=111, createdTime=2022-06-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c01ae29099c1, moduleTitle=ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c01ae29099c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853034, encodeId=36eb1853034ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Neurology：口服抗凝和二磷酸腺苷抑制剂治疗对创伤性脑损伤短期疗效的影响, objectType=article, longId=736443, objectId=1c34e364439a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c34e364439a, replyNumber=0, likeNumber=156, createdTime=2023-06-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c34e364439a, moduleTitle=Neurology：口服抗凝和二磷酸腺苷抑制剂治疗对创伤性脑损伤短期疗效的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1c34e364439a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853027, encodeId=28f0185302e22, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nature：维生素K是一种有效的铁死亡抑制剂, objectType=article, longId=735457, objectId=b47fe35457a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b47fe35457a7, replyNumber=0, likeNumber=74, createdTime=2023-01-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b47fe35457a7, moduleTitle=Nature：维生素K是一种有效的铁死亡抑制剂, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b47fe35457a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852984, encodeId=cb0a185298405, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与二甲双胍治疗2型糖尿病患者的心血管结局比较, objectType=article, longId=728165, objectId=9339e28165c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9339e28165c0, replyNumber=0, likeNumber=90, createdTime=2023-03-21, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9339e28165c0, moduleTitle=Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与二甲双胍治疗2型糖尿病患者的心血管结局比较, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9339e28165c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852903, encodeId=337e185290315, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, objectType=article, longId=300317, objectId=525d30031e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525d30031e63, replyNumber=0, likeNumber=166, createdTime=2023-02-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525d30031e63, moduleTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=525d30031e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853044, encodeId=4f791853044c4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭, objectType=article, longId=737405, objectId=2c50e37405f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c50e37405f8, replyNumber=0, likeNumber=94, createdTime=2022-11-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c50e37405f8, moduleTitle=重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2c50e37405f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852965, encodeId=f0fa1852965bf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JGH：长期使用质子泵抑制剂会增加骨质疏松症和髋部骨折的风险, objectType=article, longId=726394, objectId=169de2639423, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=169de2639423, replyNumber=0, likeNumber=88, createdTime=2022-07-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=169de2639423, moduleTitle=JGH：长期使用质子泵抑制剂会增加骨质疏松症和髋部骨折的风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=169de2639423)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852963, encodeId=e09118529632c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=中国患者研究：祸福相倚！用免疫检查点抑制剂有皮肤免疫相关不良事件，生存时间竟或翻倍？, objectType=article, longId=726357, objectId=8d0fe2635779, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d0fe2635779, replyNumber=0, likeNumber=94, createdTime=2022-09-14, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d0fe2635779, moduleTitle=中国患者研究：祸福相倚！用免疫检查点抑制剂有皮肤免疫相关不良事件，生存时间竟或翻倍？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8d0fe2635779)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852887, encodeId=e549185288eff, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=欧洲药理学杂志：组织蛋白酶 S 抑制剂 ASP1617 作为系统性红斑狼疮治疗的潜在益处, objectType=article, longId=295713, objectId=39ac295e1352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39ac295e1352, replyNumber=0, likeNumber=105, createdTime=2023-01-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39ac295e1352, moduleTitle=欧洲药理学杂志：组织蛋白酶 S 抑制剂 ASP1617 作为系统性红斑狼疮治疗的潜在益处, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=39ac295e1352)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAMA：消化疾病周（DDW）的亮点——大流行相关的结直肠癌筛查下降、质子泵抑制剂与痴呆症之间缺乏关联等

2023-01-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批

2022-11-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效

2023-05-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布

2022-12-12

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

黄金靶点NTRK第二代抑制剂VC004初步疗效喜人，国内多家有类似管线

2023-01-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

这6类人群，该如何使用质子泵抑制剂？

2022-09-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Gastroenterology：接受腹部手术的炎症性肠病患者术前肿瘤坏死因子抑制剂的治疗的安全性分析

2022-10-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

梦想照进现实！二代NTRK抑制剂获FDA孤儿药称号

2022-09-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

DOM:IL-8受体CXCR1和CXCR2的抑制剂拉达立辛治疗1型糖尿病

2022-07-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2022-12-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？

2022-12-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ASCO 2022 | FAKTION临床：capivasertib+氟维司群，改善芳香化酶抑制剂耐药MBC患者生存！

2022-06-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Neurology：口服抗凝和二磷酸腺苷抑制剂治疗对创伤性脑损伤短期疗效的影响

2023-06-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nature：维生素K是一种有效的铁死亡抑制剂

2023-01-03

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与二甲双胍治疗2型糖尿病患者的心血管结局比较

2023-03-21

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系

2023-02-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭

2022-11-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JGH：长期使用质子泵抑制剂会增加骨质疏松症和髋部骨折的风险

2022-07-31

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

中国患者研究：祸福相倚！用免疫检查点抑制剂有皮肤免疫相关不良事件，生存时间竟或翻倍？

2022-09-14

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

欧洲药理学杂志：组织蛋白酶 S 抑制剂 ASP1617 作为系统性红斑狼疮治疗的潜在益处

2023-01-22

科室
- - 订阅+
  - 更多科室
工具
服务